ReviewAssessment of Chimeric Mice with Humanized Liver as a Tool for Predicting Circulating Human Metabolites
References (60)
- et al.
Drug metabolites in safety testing
Toxicol. Appl. Pharmacol.
(2002) - et al.
An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons
Toxicol. Appl. Pharmacol.
(2003) Strategies for using in vitro screens in drug metabolism
Drug Discov. Today
(2004)- et al.
Near-completely humanized liver in mice shows human-type metabolic responses to drugs
Am. J. Pathol.
(2004) - et al.
Chimeric mice with humanized liver
Toxicology
(2008) - et al.
Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus
Hepatology
(2001) - et al.
Establishment of a humanized model of liver using NOD/Shi-scid IL2Rgnull mice
Biochem. Biophys. Res. Commun.
(2008) - et al.
Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene
Cell
(1991) - et al.
In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver
J. Pharm. Sci.
(2007) - et al.
Human P450 metabolism of warfarin
Pharmacol. Ther.
(1997)
Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R-and S-warfarin enantiomers
Biochem. Pharmacol.
(1997)
Maintenance of cytochrome P-450 in cultured adult human hepatocytes
Biochem. Pharmacol.
(1985)
Drug transporters: their role and importance in the selection and development of new drugs
Drug Metab. Pharmacokinet.
(2002)
Prediction of human disposition toward S-3H-warfarin using chimeric mice with humanized liver
Drug Metab. Pharmacokinet.
(2009)
The use of in vitro metabolism techniques in the planning and interpretation of drug safety studies
Toxicol. Pathol.
(1995)
Metabolites and safety: What are the concerns, and how should we address them?
Chem. Res. Toxicol.
(2006)
Food and Drug Administration
Guidance for Industry: Safety Testing of Drug Metabolites
(2008)
Food and Drug Administration
Guidance for Industry: M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
(2010)
Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development
Chem. Res. Toxicol.
(2009)
Metabolites in safety testing: metabolite identification strategies in discovery and development
Biopharm. Drug Dispos.
(2009)
Integrated strategies for assessment of metabolite exposure in humans during drug development: analytical challenges and clinical development considerations
Biopharm. Drug Dispos.
(2009)
Predicting circulating human metabolites: how good are we?
Chem. Res. Toxicol.
(2009)
Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites
Chem. Res. Toxicol.
(2009)
Application of chimeric mice with humanized liver for predictive ADME
Drug Metab. Rev.
(2007)
Approach for in vivo protein binding of 5-n-butyl-pyrazolo[1,5-a]pyrimidine bioactivated in chimeric mice with humanized liver by two-dimensional electrophoresis with accelerator mass spectrometry
Chem. Res. Toxicol.
(2010)
Replacement of diseased mouse liver by hepatic cell transplantation
Science
(1994)
Complete reconstitution of mouse liver with xenogeneic hepatocytes
Proc. Natl. Acad. Sci. U.S.A.
(1995)
Liver repopulation with xenogenic hepatocytes in B and T celldeficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma
Proc. Natl. Acad. Sci. U.S.A.
(1998)
A long-term hepatitis B viremia model generated by transplanting nontumorigenic immortalized human hepatocytes in Rag-2-deficient mice
Hepatology
(2000)
Hepatitis C virus replication in mice with chimeric human livers
Nat. Med.
(2001)
Cited by (0)
Copyright © 2010 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.